QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsumura, K. Articles by Kamataki, T. Search for Related Content PubMed PubMed Citation Articles by Matsumura, K. Articles by Kamataki, T.

Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene

Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo, Hokkaido, Japan (K.M., T.S., Y.T., T.O., K.K., M.F., H.Y., T.K.); and National Cancer Center Hospital, Tokyo, Japan (H.K.)

CYP3A4, the most abundant form of cytochrome P450 in the human adult liver, shows wide interindividual variation in its activity. This variability is thought to be caused largely by transcriptional and genetic factors, yet the underlying mechanisms are poorly understood. The purpose of this study was to clarify the mechanisms controlling the CYP3A4 gene transcription and to search for genetic polymorphisms in the 5'-flanking region of the CYP3A4 gene. Transient transfection of human hepatoma HepG2 cells and of normal human hepatocytes with a series of CYP3A4 promoter-luciferase reporter plasmids revealed that a region from –11.4 to –10.5 kilobases, designated the constitutive liver enhancer module of CYP3A4 (CLEM4), was important for the constitutive activation of the CYP3A4 gene. Gel shift assay using nuclear extracts prepared from HepG2 cells showed that HNF-1, HNF-4, USF1, and AP-1 interacted with CLEM4. Furthermore, the introduction of mutations into their binding sites demonstrated that essentially all sites were required for the maximal enhancer activity. Screening for genetic polymorphisms within CLEM4 in genomic DNA from French persons, we identified the novel variant, TGT insertion between –11,129 and –11,128 (–11,129_–11,128insTGT), whose allele frequency was 3.1%. The –11,129_–11,128insTGT resulted in the disruption of USF1 binding and a 36% reduction of the enhancer activity. These results suggest that CLEM4 is a constitutive enhancer of the CYP3A4 gene in the liver and that –11,129_–11,128insTGT may at least partly contribute to the interindividual variability of CYP3A4 expression.

Address correspondence to: Dr. Tetsuya Kamataki, Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, N12W6, Kita-ku, Sapporo, Hokkaido 060-0812, Japan. E-mail: kamataki{at}pharm.hokudai.ac.jp

This article has been cited by other articles:

				S.-J. Lee, S. S. Lee, H.-E. Jeong, J.-H. Shon, J.-Y. Ryu, Y. E. Sunwoo, K.-H. Liu, W. Kang, Y.-J. Park, C.-M. Shin, et al. The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals Drug Metab. Dispos., November 1, 2007; 35(11): 2095 - 2101. [Abstract] [Full Text] [PDF]

				J. S. Biggs, J. Wan, N. S. Cutler, J. Hakkola, P. Uusimaki, H. Raunio, and G. S. Yost Transcription Factor Binding to a Putative Double E-Box Motif Represses CYP3A4 Expression in Human Lung Cells Mol. Pharmacol., September 1, 2007; 72(3): 514 - 525. [Abstract] [Full Text] [PDF]

				H. Tegude, A. Schnabel, U. M. Zanger, K. Klein, M. Eichelbaum, and O. Burk Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4{alpha}: Evidence for Direct Regulation in the Intestine Drug Metab. Dispos., June 1, 2007; 35(6): 946 - 954. [Abstract] [Full Text] [PDF]

				B. L. Urquhart, R. G. Tirona, and R. B. Kim Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578. [Abstract] [Full Text] [PDF]

				C. W. Rowley, L. J. Staloch, J. K. Divine, S. P. McCaul, and T. C. Simon Mechanisms of mutual functional interactions between HNF-4{alpha} and HNF-1{alpha} revealed by mutations that cause maturity onset diabetes of the young Am J Physiol Gastrointest Liver Physiol, March 1, 2006; 290(3): G466 - G475. [Abstract] [Full Text] [PDF]

				C. P. Martinez-Jimenez, M. J. Gomez-Lechon, J. V. Castell, and R. Jover Transcriptional Regulation of the Human Hepatic CYP3A4: Identification of a New Distal Enhancer Region Responsive to CCAAT/Enhancer-Binding Protein {beta} Isoforms (Liver Activating Protein and Liver Inhibitory Protein) Mol. Pharmacol., June 1, 2005; 67(6): 2088 - 2101. [Abstract] [Full Text] [PDF]

				M. J. Ronis, Y. Chen, C.-H. Jo, P. Simpson, and T. M. Badger Diets Containing Soy Protein Isolate Increase Hepatic CYP3A Expression and Inducibility in Weanling Male Rats Exposed during Early Development J. Nutr., December 1, 2004; 134(12): 3270 - 3276. [Abstract] [Full Text] [PDF]

				C. Keshava, E. C. McCanlies, and A. Weston CYP3A4 Polymorphisms--Potential Risk Factors for Breast and Prostate Cancer: A HuGE Review Am. J. Epidemiol., November 1, 2004; 160(9): 825 - 841. [Abstract] [Full Text] [PDF]

				E. G. Schuetz Lessons from the CYP3A4 Promoter Mol. Pharmacol., February 1, 2004; 65(2): 279 - 281. [Full Text] [PDF]